Impact Factor 6.684 | CiteScore 2.7
More on impact ›
This Specialty Section includes basic, translational and clinical research articles focusing on the cellular and developmental basis of human diseases including cancer, diabetes, cardiovascular, inflammatory, and neurological diseases. Molecular Medicine is committed to understanding the molecular cell biology of all disease stages (onset, progression, and reversal). In addition to understanding disease mechanisms, the application of this understanding in the form of new diagnostic and therapeutic tools is a goal of Molecular Medicine.
This section addresses the relationship between molecules and disease phenotype. This may involve processes at the 1) molecular level (receptor tyrosine kinases, G-proteins, etc.), 2) supramolecular complexes (signaling molecule assemblies, mitochondrial protein complexes, chromatin, etc.), 3) biochemical pathways, and 4) organelle level (endosome, plasma membrane, nucleus, mitochondria). The section is particularly interested in the application of new “Omics” approaches, as they can accelerate the analysis of multiple pathways affected by disease. The section is interested in understanding the molecular mechanism of disease as well as downstream changes in cell function and biological outputs. This may include, for example, aberrant cell adhesion, cell polarity, molecular and organelle trafficking, oxidant release and DNA damage.
This section will facilitate the rapid publication of studies contributing to the understanding of the molecular basis of medicine, and to its clinical application to all diseases.
The section welcomes the following article types: Original Research, Review, Mini-Review, Methods, Perspective, Opinion, Editorial, General Commentary, Data Report, Hypothesis and Theory.
Please consider the quality and content requirements for experimental studies as listed below:
1) Descriptive studies (e.g. gene expression profiles, or transcript, protein, or metabolite levels under particular conditions or in a particular cell type) and studies consisting solely of bioinformatic investigation of publicly available genomic / transcriptomic data do not fall within the scope of the journal unless they are expanded and provide significant biological or mechanistic insight into the process being studied.
2) Quantitative analysis must be performed on a minimum number of 3 biological replicates in order to enable an assessment of significance. This includes quantitative omics studies (transcriptomics, proteomics, metabolomics) as well as phenotypic measurements, quantitative assays, and qPCR expression analysis. Studies that do not comply with these replication requirements will not be considered for review.
Indexed in: PubMed, PubMed Central (PMC), Scopus, Web of Science Science Citation Index Expanded (SCIE), Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Ulrich's Periodicals Directory, CLOCKSS, OpenAIRE
PMCID: all published articles receive a PMCID
Molecular and Cellular Pathology welcomes submissions of the following article types: Brief Research Report, Correction, Data Report, Editorial, Erratum, Field Grand Challenge, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review and Technology and Code.
All manuscripts must be submitted directly to the section Molecular and Cellular Pathology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact firstname.lastname@example.org